6ACB

Crystal structure of PDE5 in complex with inhibitor LW1805

6ACB の概要

• エントリーDOI: 10.2210/pdb6acb/pdb
• 分子名称: cGMP-specific 3',5'-cyclic phosphodiesterase, SULFATE ION, ZINC ION, ... (6 entities in total)
• 機能のキーワード: pde5 in complex with inhibitor lw1805, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 38535.94

構造登録者

Wu, D.,Huang, Y.D.,Huang, Y.Y.,Luo, H.B. (登録日: 2018-07-26, 公開日: 2018-09-19, 最終更新日: 2023-11-22)

主引用文献

Wu, D.,Huang, Y.,Chen, Y.,Huang, Y.Y.,Geng, H.,Zhang, T.,Zhang, C.,Li, Z.,Guo, L.,Chen, J.,Luo, H.B.
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
J. Med. Chem., 61:8468-8473, 2018

PubMed Abstract: To further explore the structure-activity relationship around the chromeno[2,3- c]pyrrol-9(2 H)-one scaffold, 19 derivatives as inhibitors against PDE5 were discovered. The most potent inhibitor 3 has an IC of 0.32 nM with remarkable selectivity and druglike profile. Oral administration of 3 (1.25 mg/kg) caused comparable therapeutic effects to sildenafil (10.0 mg/kg) against pulmonary arterial hypertension. Further, different binding patterns from sildenafil were revealed in cocrystal structures, which provide structural templates for discovery of highly potent PDE5 inhibitors.

PubMed: 30148362
DOI: 10.1021/acs.jmedchem.8b01209

実験手法

X-RAY DIFFRACTION (2.8 Å)